Clinical evaluation of the combination of vericiguat and ivabradine in the treatment of patients with chronic heart failure
Chen Fengyi
Fan Yanbin
Liu Yamei
Zhan Xiaolong
Sun Yun
Abstract：Objective To investigate the clinical efficacy of vericiguat combined with ivabradine in patients with chronic heart failure(CHF).Methods A total of 76 patients with CHF admitted to the Department of Cardiology,the Seventh People's Hospital of Zhengzhou from December 2022 to December 2024 were divided into the control group(n=38,treated with ivabradine and standardized basic medication)and the observation group(n=38,treated with vericiguat,ivabradine and standardized basic medication)using the random number table method.After 4 weeks of treatment,the clinical efficacy,cardiac function,inflammatory indicators and adverse reaction rates were compared between the two groups.Results The effective rate of the observation group was 92.11%(35/38),high-er than 73.68%(28/38)of the control group(χ2=4.547,P<0.05).After treatment,the left ventricular ejection fraction increased in both groups,and the observation group((45.69±4.33)%)was higher than that in the control group((40.37±3.52)%)(t=5.887,P<0.05).After treatment,the end-diastolic and end-systolic diameters of the left ventricular decreased in both groups,and the indicators of the obser-vation group((51.12±4.28)mm and(38.55±3.32)mm,respectively)were smaller than those of the control group((56.97±5.41)mm and(41.31±4.32)mm,respectively)(t=5.228,3.123,both P<0.05).After treatment,the levels of high-sensitivity C-reactive protein,tumor necrosis factor-α,and interleukin-6 in both groups decreased,and the indicators of the observation group((9.69±2.43)mg·L-1,(10.24±2.48)ng·L-1 and(37.54±7.11)ng·L-1,respectively)were lower than those in the control group((11.37±2.71)mg·L-1,(12.17±3.71)ng·L-1 and(41.21±7.41)ng·L-1,respectively)(t=2.845,2.666,2.203,all P<0.05).The incidence of adverse reactions was 13.16%(5/38)in the observation group and 5.26%(2/38)in the control group,with no statistically significant difference(χ2=0.560,P>0.05).Conclusion The combination of vericiguat and ivabradine demonstrates a remarkable therapeutic effect on CHF,effectively improv-ing the cardiac function and inflammatory markers in CHF patients with a favorable safety profile.
Keywords：VericiguatIvabradineChronic heart failureCardiac functionInflammatory markers
Publication Date：2025-09-25
Online Publishing Date：2025-10-10(First online date of this platform, not the publication date of the document)
Pages：5( 1033-1037 )